
Novo Nordisk to Unveil New Hemophilia Clinical Data in Paris
At the upcoming International Society on Thrombosis and Haemostasis Congress in Paris, Novo Nordisk will present a suite of new findings from its hemophilia portfolio, headlined by long-term efficacy and safety results for the investigational bispecific antibody denecimig, also known as Mim8.























